Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne (NASDAQ: TECH) has released its 2025 Corporate Sustainability Report, highlighting significant progress in environmental stewardship and innovation. The company achieved a notable 40% reduction in Scope 1 and 2 emissions through renewable electricity adoption at its Minneapolis headquarters.
Under CEO Kim Kelderman's leadership, Bio-Techne has committed to setting science-based GHG reduction targets for validation by SBTi in 2026. The company continues to advance breakthroughs in various diseases while implementing enhanced governance measures, including new Board oversight of AI and completion of climate assessments.
The report emphasizes Bio-Techne's focus on sustainable innovation across its life sciences portfolio, particularly in cell therapy, proteomic instruments, and precision diagnostics.
CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.
Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.
ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded eight G-Rex Grants totaling nearly $2 million to California Institute for Regenerative Medicine (CIRM) Manufacturing Network program recipients. The grants support cell and gene therapy (CGT) manufacturing advancement in California.
The grants, ranging from $125,000 to $300,000, were awarded to prestigious institutions including UC San Diego, City of Hope, Stanford Medicine, USC/CHLA, UC Davis, UCSF, UCLA, and Cedars Sinai. These grants are part of ScaleReady's $40 million initiative to advance CGT development and manufacturing.
Recipients will receive exclusive support from ScaleReady's consortium of G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality control, regulatory affairs, and CGT business operations.
Bio-Techne (NASDAQ: TECH) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 10:15 AM EDT, the Baird Global Healthcare Conference on September 9 at 9:05 AM EDT, and the Morgan Stanley Global Healthcare Conference on September 10 at 10:45 AM EDT.
Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website under the IR Calendar page.
ScaleReady (NYSE:TECH) has awarded a $300,000 G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory to develop a modular CAR T-cell manufacturing platform. The grant will support optimization of key CAR-T cell manufacturing steps through Design of Experiments (DoE) evaluation.
The Gates Institute will receive early access to CellReady's G-CAR-T™, a standardized CAR-T drug product manufacturing operation. ScaleReady's G-Rex Grant Program has authorized over $40M of products to grant recipients to advance cell and gene therapy development and manufacturing.
Additionally, ScaleReady announced a new free program called LEAN Cell & Gene™, launched in partnership with Hanson Wade, aimed at improving efficiency in CGT manufacturing.
Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025.
The company, a global life sciences leader providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of $1.2 billion in fiscal 2025 and employs approximately 3,100 people worldwide. Bio-Techne's products support scientific research into biological processes, disease progression, drug discovery, and clinical diagnostics.
Bio-Techne (NASDAQ: TECH) reported its Q4 and full-year fiscal 2025 results, with Q4 organic revenue growing 3% (4% reported) to $317.0 million. Full-year organic revenue increased 5% to $1.2 billion. The company reported Q4 GAAP EPS of $(0.11) versus $0.25 year-over-year, while adjusted EPS improved to $0.53 from $0.49.
The Protein Sciences segment showed strong performance with 4% organic growth (6% reported) in Q4. Notably, Bio-Techne announced the divestiture of its Exosome Diagnostics business, resulting in an $83.1 million impairment loss. The company's Q4 adjusted operating margin was 32.0%, down from 33.5% in the previous year, impacted by unfavorable product mix.
Bio-Techne (NASDAQ: TECH) has announced the divestiture of its Exosome Diagnostics business to Mdxhealth SA. The deal includes the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory, and related assets. Bio-Techne will maintain access to the proprietary exosome-based technology for kit development in its precision diagnostics segment.
Under the agreement terms, Bio-Techne will receive $5 million in MDXH stock plus future considerations. The transaction is expected to close in Q1 of Bio-Techne's fiscal 2026. The strategic move aims to strengthen Bio-Techne's focus on developing high-value products for life science research and clinical diagnostics markets while improving its operating margin profile.
ScaleReady (NYSE:TECH) has awarded a $100,000 G-Rex® Grant to Sidra Medicine, a women and children's hospital in Qatar. The grant will support the development of a CD19 CAR-T cell therapy product for pediatric oncology, including access to G-CART™ process and implementation of GMP-compliant production systems.
The grant is part of ScaleReady's broader initiative that has committed over $40 million in no-cost products to recipients. Recipients can receive up to $300,000 in individual grants and gain access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners. Additionally, ScaleReady has launched a free LEAN Cell & Gene™ event series in partnership with Hanson Wade to promote efficient CGT manufacturing.
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded $665,000 in G-Rex® Grants to three investigators at the University of Minnesota's Center for Genome Engineering.
The grants were distributed to: Dr. Branden Moriarity ($300,000) for CAR-NK cell therapy development for ovarian cancer, Dr. Beau Webber ($240,000) for TIL therapy development for solid tumors, and Dr. Joseph Skeate ($125,000) for T-cell therapy development targeting Batten Disease.
ScaleReady's G-Rex Grant Program has now exceeded $40M in no-cost product commitments. The company has also launched a new free program called LEAN Cell & Gene™ in partnership with Hanson Wade to promote efficient CGT manufacturing practices.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
